Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose
- First Online:
- Cite this article as:
- Breccia, M., Cilloni, D., Cannella, L. et al. Cancer Chemother Pharmacol (2009) 63: 1161. doi:10.1007/s00280-008-0858-8
Imatinib is the treatment of choice for FIP1L1-PDGFRα (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.